Canopy Rivers Portfolio Company Receives Approval to Research UV Light Impact on Cannabis Plant

Published: January 9, 2020

Canopy Rivers Portfolio Company Receives Approval to Research UV Light Impact on Cannabis Plant

Canopy Rivers Inc. portfolio company BioLumic Ltd. has received approval from the New Zealand Ministry of Health to apply its proprietary ultraviolet (“UV”) light technology to medical cannabis. While BioLumic’s approach has been successful in increasing yields in certain crops, such as strawberries, by up to 60%, this approval marks the first time the company’s UV light technology will be used on cannabis. BioLumic hopes that its research will show increased yields in the cannabis plant and help producers meet the rising demand for medical cannabis and cannabis-derived products.

To bring its cannabis research program to life, BioLumic is partnering with two established cannabis companies. The company will work with Canada-based cannabis cultivator and Canopy Rivers portfolio company James E. Wagner Cultivation Corporation (“JWC”) (TSXV: JWCA, OTCQX: JWCAF), as well as Auckland-based medical cannabis company Helius Therapeutics. With the support of these partnerships, BioLumic plans to begin conducting medical cannabis commercial trials in New Zealand and Canada by June 2020.

“The partnership between BioLumic and JWC is another sign of strong collaboration in the Canopy Rivers ecosystem,” said Narbé Alexandrian, President & CEO, Canopy Rivers. “We expect that BioLumic’s expertise in non-cannabis agriculture technology will help cannabis cultivators like JWC produce high-yield, sustainable strains that meet consumer demands and patient needs.”

BioLumic’s UV light technology treats plants to increase yields and enable plants to more effectively defend themselves against disease or pest attacks. By exposing seeds and seedlings to short duration UV treatments, BioLumic aims to increase yields and improve tolerance to drought, diseases, and pests.

“Working with Canopy Rivers has opened the door for us to expand into cannabis, and that starts with the application of our technology to the cannabis plant,” said Jason Wargent, Chief Science Officer, BioLumic. “From accessing capital to bring on new staff in science and AI, to introductions to companies such as JWC, we believe our ongoing relationship with Canopy Rivers is a catalyst for building the industry’s understanding of how to improve the way cannabis is grown.”

“The BioLumic research program is an exciting opportunity to push the boundaries of our knowledge of cannabis cultivation,” said Nathan Woodworth, President & CEO, JWC. “JWC is committed to expanding our understanding of advanced cultivation techniques as they apply to cannabis, and our partnership with BioLumic is just one of the ways we are meeting this commitment.”

For its cannabis research program, BioLumic will combine photogenics – the control of plant signalling responses to UV light – and artificial intelligence (“AI”) to focus on improving the yield of the fast-growing cannabis crop, with a focus on cannabinoids such as cannabidiol. BioLumic has hired additional science and AI-focused staff at its Palmerston North, New Zealand facility to accelerate its cannabis research program.

Canopy Rivers invested in BioLumic in May 2019 as part of a Series A financing round led by Finistere Ventures, an agriculture technology venture capital fund supported by industry leaders Bayer and Nutrien. Canopy Rivers’ strategic investment marked the venture capital firm’s first investment in agriculture sciences.

Recent News

View All News Items

Latest Article

Legalization 2.0: IP and Regulatory Considerations for Edibles, Extracts and Topicals

Legalization 2.0: IP and Regulatory Considerations for Edibles, Extracts and Topicals

The legalization of cannabis edibles, extracts and topicals will expand the cannabis market and create new opportunities for producers, innovators and investors. According to a recent report from Deloitte, the Canadian market for these new cannabis products is expected to be worth $2.7 billion annually, with edibles accounting for more than half ($1.6 billion).

 

Read Article